OIG: Nursing Homes Used False Schizophrenia Diagnoses

WASHINGTON, D.C. — The U.S. Department of Health and Human Services Office of Inspector General released a report on March 19, 2026, revealing that nursing homes across the country inappropriately diagnosed residents with schizophrenia in order to conceal the misuse of antipsychotic drugs and artificially inflate their Medicare star ratings.

The investigation, designated report number OEI-02-23-00201, represents the second in a two-part series by the OIG examining antipsychotic drug use in long-term care facilities. According to the OIG's findings, a comprehensive review of 40 nursing home inspections completed by the Centers for Medicare and Medicaid Services uncovered a troubling pattern of false psychiatric diagnoses being used as a tool to evade federal quality oversight.

At the center of the issue is a CMS quality measure that tracks the percentage of nursing home residents receiving antipsychotic medications. This metric directly affects a facility's star rating — the primary tool families use when selecting a nursing home. However, residents who carry a schizophrenia diagnosis are excluded from the calculation, according to the OIG report. That exclusion created a perverse financial incentive: by labeling residents as schizophrenic, facilities could administer antipsychotic drugs without those prescriptions counting against their public quality scores.

The OIG's review found that this was not an isolated problem. According to the report, investigators identified cases in which medical directors personally made inappropriate schizophrenia diagnoses specifically to justify prescribing antipsychotic medications. The report also found that facilities used the fraudulent diagnoses to circumvent Medicare safeguards that were specifically designed to protect nursing home residents from unnecessary or harmful drugging.

The Dangers of Antipsychotic Misuse

The misuse of antipsychotic drugs in nursing homes has been a decades-long concern for federal regulators and patient advocates. These medications carry sedative properties and can effectively be used as chemical restraints — drugging residents into compliance rather than addressing underlying behavioral or medical needs through appropriate care. Federal regulations classify the use of drugs for staff convenience, rather than to treat a diagnosed condition, as a form of chemical restraint.

The stakes are particularly high for the elderly population most commonly found in nursing homes. Antipsychotic drugs carry an FDA black box warning — the agency's most serious safety alert — indicating an increased risk of death when administered to elderly patients with dementia. Despite this warning, according to the OIG, nursing homes continued to prescribe these medications while using false diagnoses to hide the practice from regulators and the public.

By assigning inappropriate schizophrenia diagnoses, according to the OIG report, nursing homes directly compromised the care their residents received. A false psychiatric diagnosis can follow a patient through their medical records, potentially affecting all future treatment decisions, medication management, and care planning.

CMS Inspection History

The OIG's findings highlight systemic weaknesses in how CMS monitors antipsychotic drug use across the nursing home industry. The quality measure system, while well-intentioned, contained a loophole that facilities exploited on a wide scale. According to CMS data, the agency tracks antipsychotic prescribing rates as part of its Five-Star Quality Rating System, which assigns facilities between one and five stars across multiple care categories. Facilities with lower rates of antipsychotic use receive better quality scores, creating a direct link between prescribing patterns and public reputation.

The OIG report noted that CMS has taken some steps in recent years to address concerns about rising schizophrenia diagnoses in nursing homes, but the inspector general found these efforts insufficient. The report recommended that CMS build on its existing efforts to reduce inappropriate schizophrenia diagnoses, expand its use of data analytics to monitor facilities' diagnostic patterns and target oversight accordingly, and increase efforts to ensure residents and their families are fully informed when antipsychotic drugs are prescribed.

According to the report, CMS did not explicitly concur or nonconcur with any of the three recommendations. The OIG stated that it encourages the agency to re-examine its position when issuing its Final Management Decision.

Ownership & Operations

The OIG report examined the issue as an industry-wide problem rather than targeting individual facilities or ownership groups. The findings suggest that the practice of using false schizophrenia diagnoses cut across different types of nursing home operators, indicating a systemic issue driven by the financial incentives embedded in the star rating system. The involvement of medical directors in making inappropriate diagnoses, as documented by the OIG, raises serious questions about clinical governance and oversight within facilities of all sizes and ownership structures.

Resources for Families

Families who suspect a loved one may have been inappropriately diagnosed or is receiving unnecessary antipsychotic medications in a nursing home should take immediate action. Key steps include requesting a full copy of the resident's medical records, asking for a detailed explanation of any psychiatric diagnosis, and inquiring whether antipsychotic medications have been prescribed.

Concerns can be reported to the National Long-Term Care Ombudsman Resource Center at 1-800-677-1116. Ombudsman programs advocate for residents of nursing homes and other long-term care facilities in every state. Families can also visit [ltcombudsman.org](https://ltcombudsman.org) to locate their local ombudsman program.

Complaints about nursing home care can also be filed directly with your state's health department survey and certification agency, which conducts inspections on behalf of CMS. Suspected fraud, including inappropriate diagnoses made for financial gain, can be reported to the HHS Office of Inspector General hotline at 1-800-HHS-TIPS (1-800-447-8477).

Federal law requires that nursing homes obtain informed consent before administering antipsychotic medications and that residents have the right to refuse treatment. Families should not hesitate to ask questions, request care conferences, and advocate for their loved ones' right to be free from unnecessary drugging.